Publications

1. Valle LF, Kishan AU, Franco A, Ma TM, Nikitas J, Farrell M, Chang AJ, Nickols NG, Steinberg ML. Selecting the optimal radiation modality in prostate cancer.. Clinical advances in hematology & oncology : H&O, 2023.
2. Frank CH, Ramesh P, Lyu Q, Ruan D, Park SJ, Chang AJ, Venkat PS, Kishan AU, Sheng K. Analytical HDR prostate brachytherapy planning with automatic catheter and isotope selection.. Medical physics, 2023.
3. Corkum MT, Buyyounouski MK, Chang AJ, Chung HT, Chung P, Cox BW, Crook JM, Davis BJ, Frank SJ, Henriquez I, Horwitz EM, Hoskin P, Hsu IC, Keyes M, King MT, Kollmeier MA, Krauss DJ, Kukielka AM, Morton G, Orio PF, Pieters BR, Potters L, Rossi PJ, Showalter TN, Solanki AA, Song D, Vanneste B, Vigneault E, Wojcieszek PA, Zelefsky MJ, Kamrava M. Salvage prostate brachytherapy in radiorecurrent prostate cancer: An international Delphi consensus study.. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2023.
4. Valle LF, Jiang T, Weiner AB, Reiter RE, Rettig MB, Shen J, Chang AJ, Nickols NG, Steinberg ML, Kishan AU. Multimodality Therapies for Localized Prostate Cancer.. Current oncology reports, 2023.
5. Patel SA, Liu Y, Solanki AA, Baumann BC, Efstathiou JA, Jani AB, Chang AJ, Fischer-Valuck B, Royce TJ. Bladder only versus bladder plus pelvic lymph node chemoradiation for muscle-invasive bladder cancer.. Urologic oncology, 2023.
6. Patel SA, Baumann B, Michalski J, Brenneman R, Zheng B, Gay H, Ferraro D, Brown SA, Chang AJ, Rossi PJ, Fischer-Valuck BW. Association of Brachytherapy Boost with Overall Survival for Gleason 9-10 Prostate Cancer: The Impact of Primary versus Secondary Pattern 5.. Brachytherapy, 2023.
7. Shee K, de la Calle CM, Chang AJ, Wong AC, Feng FY, Gottschalk AR, Carroll PR, Nguyen HG. Addition of Enzalutamide to Leuprolide and Definitive Radiation Therapy Is Tolerable and Effective in High-Risk Localized or Regional Nonmetastatic Prostate Cancer: Results From a Phase 2 Trial.. Advances in radiation oncology, 2022.
8. Kundu P, Lin EY, Yoon SM, Parikh NR, Ruan D, Kishan AU, Lee A, Steinberg ML, Chang AJ. Rectal Radiation Dose and Clinical Outcomes in Prostate Cancer Patients Treated With Stereotactic Body Radiation Therapy With and Without Hydrogel.. Frontiers in oncology, 2022.
9. Phuong C, Chan JW, Ni L, Wall P, Mohamad O, Wong AC, Hsu IC, Chang AJ. Safety of accelerated hypofractionated whole pelvis radiation therapy prior to high dose rate brachytherapy or stereotactic body radiation therapy prostate boost.. Radiation oncology (London, England), 2022.
10. Medina R, Macyszyn L, Lim AS, Attiah M, Kafka-Peterson K, Kaprelian T, Hegde JV, Venkat P, Lee A, Park SJ, Chang AJ. High-Dose Rate Interstitial Spine Brachytherapy Using an Intraoperative Mobile Computed Tomography-Guided Surgical Navigation System.. Operative neurosurgery (Hagerstown, Md.), 2021.
11. Xiang M, Chang AJ, Chamie K, Drakaki A, Pollom EL, Steinberg ML, Kishan AU. Trends and Predictors of Hypofractionated and Intensity-Modulated Radiotherapy for Organ Preservation in Bladder Cancer.. Clinical genitourinary cancer, 2021.
12. Shah C, Vicini F, Beriwal S, Thaker N, Frank SJ, Rossi P, Orio P, Chang AJ, Joshi N, Campbell SR, Naghavi A, Chao S, Kamrava M, Deufel CL, Mourtada F, Suh JH. American Brachytherapy Society radiation oncology alternative payment model task force: Quality measures and metrics for brachytherapy.. Brachytherapy, 2021.
13. Boyce-Fappiano D, Nguyen KA, Gjyshi O, Manzar G, Abana CO, Klopp AH, Kamrava M, Orio PF, Thaker NG, Mourtada F, Venkat P, Chang AJ. Socioeconomic and Racial Determinants of Brachytherapy Utilization for Cervical Cancer: Concerns for Widening Disparities.. JCO oncology practice, 2021.
14. Genshaft SJ, Suh RD, Abtin F, Baerlocher MO, Chang AJ, Dariushnia SR, Devane AM, Faintuch S, Himes EA, Lisberg A, Padia S, Patel S, Tam AL, Yanagawa J. Society of Interventional Radiology Multidisciplinary Position Statement on Percutaneous Ablation of Non-small Cell Lung Cancer and Metastatic Disease to the Lungs: Endorsed by the Canadian Association for Interventional Radiology, the Cardiovascular and Interventional Radiological Society of Europe, and the Society of Interventional Oncology.. Journal of vascular and interventional radiology : JVIR, 2021.
15. Kishan AU, Karnes RJ, Romero T, Wong JK, Motterle G, Tosoian JJ, Trock BJ, Klein EA, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Levin-Epstein R, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Braccioforte M, Huland H, Tran PT, Martin S, Martínez-Monge R, Krauss DJ, Abu-Isa EI, Alam R, Schwen Z, Chang AJ, Pisansky TM, Choo R, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Boutros PC, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Chong N, Kupelian PA, D'Amico AV, Rettig MB, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Horwitz EM, Tendulkar RD, Tilki D. Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features.. JAMA network open, 2021.
16. Yoon SM, Suh R, Abtin F, Moghanaki D, Genshaft S, Kamrava M, Drakaki A, Liu S, Venkat P, Lee A, Chang AJ. Outcomes with multi-disciplinary management of central lung tumors with CT-guided percutaneous high dose rate brachyablation.. Radiation oncology (London, England), 2021.
17. Boyce-Fappiano D, Ning MS, Gjyshi O, Mesko S, Pasalic D, Chang AJ, Orio PF, Thaker NG. Payment Methodology for the Radiation Oncology Alternative Payment Model: Implications for Practices and Suggestions for Improvement.. JCO oncology practice, 2021.
18. Cohen JG, Chang AJ. Use of stereotactic body radiotherapy in gynecologic cancers: Local control with systemic treatment implications.. Gynecologic oncology, 2020.
19. Nguyen KA, Lee A, Patel SA, Chakravorty A, Yu JB, Kishan AU, Chang AJ. Trends in Use and Comparison of Stereotactic Body Radiation Therapy, Brachytherapy, and Dose-Escalated External Beam Radiation Therapy for the Management of Localized, Intermediate-Risk Prostate Cancer.. JAMA network open, 2020.
20. Levin-Epstein R, Cook RR, Wong JK, Stock RG, Jeffrey Demanes D, Collins SP, Aghdam N, Suy S, Mantz C, Katz AJ, Nickols NG, Miszczyk L, Napieralska A, Namysl-Kaletka A, Prionas ND, Bagshaw H, Buyyounouski MK, Cao M, Mahal BA, Shabsovich D, Dang A, Yuan Y, Rettig MB, Chang AJ, Jackson WC, Spratt DE, Lehrer EJ, Zaorsky NG, Kupelian PA, Steinberg ML, Horwitz EM, Jiang NY, Kishan AU. Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients.. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2020.
21. Kishan AU, Chu FI, King CR, Seiferheld W, Spratt DE, Tran P, Wang X, Pugh SE, Sandler KA, Bolla M, Maingon P, De Reijke T, Nickols NG, Rettig M, Drakaki A, Liu ST, Reiter RE, Chang AJ, Feng FY, Sajed D, Nguyen PL, Kupelian PA, Steinberg ML, Boutros PC, Elashoff D, Collette L, Sandler HM. Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials.. European urology, 2019.
22. Tom MC, Joshi N, Vicini F, Chang AJ, Hong TS, Showalter TN, Chao ST, Wolden S, Wu AJ, Martin D, Husain Z, Badiyan SN, Kolar M, Sherertz T, Mourtada F, Cohen GN, Shah C. The American Brachytherapy Society consensus statement on intraoperative radiation therapy.. Brachytherapy, 2019.
23. Xu MJ, Chen KS, Chang AJ, Lazar A, Shinohara K, Cunha JAM, Hsu IC. Single-fraction brachytherapy as monotherapy for early-stage prostate cancer: The UCSF experience.. Brachytherapy, 2019.
24. Wang C, Raldow AC, Nickols NG, Nguyen PL, Spratt DE, Dess RT, Yu JB, King CR, Chu FI, Chamie K, Litwin MS, Saigal CS, Reiter RE, Liu ST, Rettig MB, Chang AJ, Steinberg ML, Kupelian PA, Kishan AU. Underutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer.. European urology oncology, 2019.
25. Wu SY, Boreta L, Shinohara K, Nguyen H, Gottschalk AR, Hsu IC, Roach M, Westphalen AC, Feng FY, Carroll PR, Chang AJ, Hope TA. Impact of Staging 68Ga-PSMA-11 PET Scans on Radiation Treatment Plansin Patients With Prostate Cancer.. Urology, 2018.
26. Valdes G, Chang AJ, Cunnan A, Solberg TD, Hsu IC, Interian Y, Owen K, Jensen ST, Ungar LH. In Reply to Gensheimer and Trister.. International journal of radiation oncology, biology, physics, 2018.
27. Chang AJ, McBride S, Keyes M, Chung HT, Davis BJ, Cox BW, Crook J, Demanes DJ, Hsu IC, Kamrava M, Krauss DJ, Morton G, Orio Iii PF, Roach Iii M, Venkat PS, Vigneault E, Zelefsky MJ. The American Brachytherapy Society and the American Radium Society Appropriate Use Criteria Genitourinary Committee Endorse the American Society of Clinical Oncology/Cancer Care Ontario Guidelines.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018.
28. Valdes G, Chang AJ, Interian Y, Owen K, Jensen ST, Ungar LH, Cunha A, Solberg TD, Hsu IC. Salvage HDR Brachytherapy: Multiple Hypothesis Testing Versus Machine Learning Analysis.. International journal of radiation oncology, biology, physics, 2018.
29. Wu SY, Boreta L, Wu A, Cheung JP, Cunha JAM, Shinohara K, Chang AJ. Improved rectal dosimetry with the use of SpaceOAR during high-dose-rate brachytherapy.. Brachytherapy, 2017.
30. Truillet C, Oh HLJ, Yeo SP, Lee CY, Huynh LT, Wei J, Parker MFL, Blakely C, Sevillano N, Wang YH, Shen YS, Olivas V, Jami KM, Moroz A, Jego B, Jaumain E, Fong L, Craik CS, Chang AJ, Bivona TG, Wang CI, Evans MJ. Imaging PD-L1 Expression with ImmunoPET.. Bioconjugate chemistry, 2017.
31. Kunogi H, Cunha JAM, Chang AJ, Gadzinski AJ, Shinohara K, Hsu IC. A novel urethral sparing technique for high-dose-rate prostate brachytherapy after transurethral resection of the prostate.. Brachytherapy, 2017.
32. Paulsson AK, Yom SS, Anwar M, Pinnaduwage D, Sudhyadhom A, Gottschalk AR, Chang AJ, Descovich M. Respiration-Induced Intraorgan Deformation of the Liver: Implications for Treatment Planning in Patients Treated With Fiducial Tracking.. Technology in cancer research & treatment, 2017.
33. Choi JY, Yang J, Noworolski SM, Behr S, Chang AJ, Simko JP, Nguyen HG, Carroll PR, Kurhanewicz J, Seo Y. 18F Fluorocholine Dynamic Time-of-Flight PET/MR Imaging in Patients with Newly Diagnosed Intermediate- to High-Risk Prostate Cancer: Initial Clinical-Pathologic Comparisons.. Radiology, 2016.
34. Zhang L, Johnson J, Gottschalk AR, Chang AJ, Hsu IC, Roach M, Seymour ZA. Receiver operating curves and dose-volume analysis of late toxicity with stereotactic body radiation therapy for prostate cancer.. Practical radiation oncology, 2016.
35. Baumann BC, Bosch WR, Bahl A, Birtle AJ, Breau RH, Challapalli A, Chang AJ, Choudhury A, Daneshmand S, El-Gayed A, Feldman A, Finkelstein SE, Guzzo TJ, Hilman S, Jani A, Malkowicz SB, Mantz CA, Master V, Mitra AV, Murthy V, Porten SP, Richaud PM, Sargos P, Efstathiou JA, Eapen LJ, Christodouleas JP. Development and Validation of Consensus Contouring Guidelines for Adjuvant Radiation Therapy for Bladder Cancer After Radical Cystectomy.. International journal of radiation oncology, biology, physics, 2016.
36. Raleigh DR, Chang AJ, Tomlin B, Cunha JA, Braunstein SE, Shinohara K, Gottschalk AR, Roach M, Hsu IC. Patient- and treatment-specific predictors of genitourinary function after high-dose-rate monotherapy for favorable prostate cancer.. Brachytherapy, 2015.
37. Jalloh M, Leapman MS, Cowan JE, Shinohara K, Greene KL, Roach M, Chang AJ, Chan JM, Simko JP, Carroll PR. Patterns of Local Failure following Radiation Therapy for Prostate Cancer.. The Journal of urology, 2015.
38. Seymour ZA, Chang AJ, Zhang L, Kirby N, Descovich M, Roach M, Hsu IC, Gottschalk AR. Dose-volume analysis and the temporal nature of toxicity with stereotactic body radiation therapy for prostate cancer.. Practical radiation oncology, 2015.
39. Raleigh DR, Hsu IC, Braunstein S, Chang AJ, Simko JP, Roach M. Bladder wall recurrence of prostate cancer after high-dose-rate brachytherapy.. Brachytherapy, 2014.
40. Chang AJ. Editorial comment.. Urology, 2014.
41. Chang AJ, Autio KA, Roach M, Scher HI. High-risk prostate cancer-classification and therapy.. Nature reviews. Clinical oncology, 2014.
42. Anwar M, Weinberg V, Chang AJ, Hsu IC, Roach M, Gottschalk A. Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir.. Radiation oncology (London, England), 2014.
43. Beaino W, Guo Y, Chang AJ, Anderson CJ. Roles of Atox1 and p53 in the trafficking of copper-64 to tumor cell nuclei: implications for cancer therapy.. Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry, 2014.
44. Nedrow JR, White AG, Modi J, Nguyen K, Chang AJ, Anderson CJ. Positron emission tomographic imaging of copper 64- and gallium 68-labeled chelator conjugates of the somatostatin agonist tyr3-octreotate.. Molecular imaging, 2014.
45. Chang AJ, Sohn R, Lu ZH, Arbeit JM, Lapi SE. Detection of rapalog-mediated therapeutic response in renal cancer xenografts using ⁶⁴Cu-bevacizumab immunoPET.. PloS one, 2013.
46. Chen CP, Weinberg V, Shinohara K, Roach M, Nash M, Gottschalk A, Chang AJ, Hsu IC. Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes.. International journal of radiation oncology, biology, physics, 2013.
47. Garsa AA, Chang AJ, Dewees T, Spencer CR, Adkins DR, Dehdashti F, Gay HA, Thorstad WL. Prognostic value of 18F-FDG PET metabolic parameters in oropharyngeal squamous cell carcinoma.. Journal of radiation oncology, 2013.
48. Chang AJ, Roach M. Cautious optimism for extreme dose escalation in prostate cancer.. European urology, 2013.
49. Chang AJ, De Silva RA, Lapi SE. Development and characterization of 89Zr-labeled panitumumab for immuno-positron emission tomographic imaging of the epidermal growth factor receptor.. Molecular imaging, 2013.
50. Gay HA, Jin JY, Chang AJ, Ten Haken RK. Utility of normal tissue-to-tumor α/β ratio when evaluating isodoses of isoeffective radiation therapy treatment plans.. International journal of radiation oncology, biology, physics, 2012.
51. Chang AJ, Roach M. Radium-223: down to the bone, and less is more.. Oncology (Williston Park, N.Y.), 2012.
52. Chang AJ, Desilva R, Jain S, Lears K, Rogers B, Lapi S. 89Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors.. Pharmaceuticals (Basel, Switzerland), 2012.
53. Chang AJ, Zhao H, Wahab SH, Moore K, Taylor M, Zoberi I, Powell SN, Klein EE. Video surface image guidance for external beam partial breast irradiation.. Practical radiation oncology, 2011.
54. Chang AJ, Dehdashti F, Bradley JD. The role of positron emission tomography for non-small cell lung cancer.. Practical radiation oncology, 2011.
55. Chang AJ, Richardson S, Grigsby PW, Schwarz JK. Split-field helical tomotherapy with or without chemotherapy for definitive treatment of cervical cancer.. International journal of radiation oncology, biology, physics, 2010.
56. Chang AJ, Bradley JD. Clinical perspectives on dose escalation for non-small-cell lung cancer.. Clinical lung cancer, 2010.
57. Chang AJ, Song DH, Wolfe MM. Attenuation of peroxisome proliferator-activated receptor gamma (PPARgamma) mediates gastrin-stimulated colorectal cancer cell proliferation.. The Journal of biological chemistry, 2006.
58. Yao M, Zhou W, Sangha S, Albert A, Chang AJ, Liu TC, Wolfe MM. Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005.
59. Moore TC, Jepeal LI, Boylan MO, Singh SK, Boyd N, Beer DG, Chang AJ, Wolfe MM. Gastrin stimulates receptor-mediated proliferation of human esophageal adenocarcinoma cells.. Regulatory peptides, 2004.
60. Chang AJ, Dixit V, Saab S. Fulminant Hepatic Failure.. Current treatment options in gastroenterology, 2003.
61. Saab S, Chang AJ, Comulada S, Geevarghese SK, Anselmo RD, Durazo F, Han S, Farmer DG, Yersiz H, Goldstein LI, Ghobrial RM, Busuttil RW. Outcomes of hepatitis C- and hepatitis B core antibody-positive grafts in orthotopic liver transplantation.. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2003.